Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lisata Therapeutics, Inc. - Common Stock (NQ: LSTA ) 2.950 UNCHANGED Streaming Delayed Price Updated: 3:10 PM EDT, Aug 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 2.950 Bid (Size) 2.700 (3) Ask (Size) 3.650 (10) Prev. Close 2.950 Today's Range 2.950 - 2.950 52wk Range 1.950 - 3.830 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024 August 12, 2024 LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 12, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Performance YTD +6.12% +6.12% 1 Month -16.67% -16.67% 3 Month -4.99% -4.99% 6 Month +2.79% +2.79% 1 Year +9.26% +9.26% More News Read More Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024 August 05, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy July 18, 2024 From Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology Via GlobeNewswire Recap: Lisata Therapeutics Q4 Earnings February 29, 2024 Via Benzinga EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy July 18, 2024 Via Benzinga Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma July 16, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model July 10, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial June 13, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events May 28, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer May 20, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results May 13, 2024 Via News Direct Exposures Product Safety Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results May 13, 2024 Via TheNewswire.com Exposures Product Safety LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q1 2024 May 09, 2024 Via InvestorPlace Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events May 08, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024 May 02, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma April 23, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma April 09, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events April 03, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma March 21, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Life Science Virtual Investor Forum Presentations Now Available for Online Viewing March 08, 2024 From Virtual Investor Conferences Via GlobeNewswire Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024 March 05, 2024 From Virtual Investor Conferences Via GlobeNewswire Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ March 04, 2024 From Virtual Investor Conferences Via GlobeNewswire Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update February 29, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
